Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.22, sa.3, ss.533-536, 2016 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 22 Sayı: 3
- Basım Tarihi: 2016
- Doi Numarası: 10.1177/1078155215572930
- Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.533-536
- Anahtar Kelimeler: Melanoma, ipilimumab, cytotoxic T-lymphocyte antigen-4, radiotherapy, dermatitis, RADIATION-THERAPY, LOCAL RADIATION, HIGH-RISK, ADJUVANT RADIOTHERAPY, MELANOMA, INHIBITION, LYMPHADENECTOMY, IMMUNOTHERAPY, ANTIBODY, PATIENT
- Akdeniz Üniversitesi Adresli: Evet
Özet
Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.